Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Breast Cancer Clinical Trial

Official title:

An Exploratory, Phase I, Open Label, Multi-Center, Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01362712
• Other study ID #: CP-18 100
• Status: Terminated
• Phase: Phase 1
• First received: May 13, 2011
• Last updated: May 17, 2012
• Start date: May 2011
• Est. completion date: April 2012

Study information

• Verified date: May 2012
• Source: Siemens Molecular Imaging
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This trial will be the first trial for the IP, [F-18]CP-18, and will be conducted as an exploratory Phase I trial designed to collect information as this IP is administered and evaluated for the first time in humans. The trial will evaluate safety, biodistribution and dosimetry data in normal subjects and the trial will evaluate safety, biodistribution and tumor to background imaging data, and correlate image data with caspase 3 activity level on a surgical specimen analyzed by immunohistochemistry in the cancer subjects. All study results will be evaluated and analyzed in order to consider the design for future clinical trials. The information collected under this exploratory, Phase I study will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management of the subject.

Description:

The Sponsor intends to conduct this exploratory investigation of [F-18]CP-18 in human subjects. In this study of [F-18]CP-18, it is intended to assess its biodistribution, PET scan resolution, signal to background ratio in tumor, and any adverse events. This exploratory Phase I study will be used to obtain the necessary safety and dosimetry data in normal subjects and to collect drug biodistribution data, and tumor to background imaging data in breast cancer subjects. The information collected from this study will not be used for diagnostic purposes, to assess the subject's response to therapy, or for clinical management of the subject.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: April 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

For Normal Volunteers

• Subject is a female or male of any race / ethnicity between 21 to 75 years old at the time of the investigational product administration

• Subject or subject's legally acceptable representative provides written informed consent

• Subject is capable of complying with study procedures

• Subject must have renal functions values as defined by laboratory results within the following ranges:

• Serum creatinine = 2x institutional upper limits of normal

For Cancer Patients

• Patient is a female or male of any race / ethnicity between 21 to 75 years old at the time of the investigational product administration

• Patients or subject's legally acceptable representative provides written informed consent

• Patient is capable of complying with study procedures

• Patient must have renal functions values as defined by laboratory results within the following ranges:

• Serum creatinine = 2x institutional upper limits of normal

• BUN < 2X institutional upper limits of normal

• Patient must have a confirmed diagnosis of stage IIB/IIIA/IIIB, locally advanced breast cancer

• Patient has been or will be scheduled for the surgical resection of tumor(s) after undergoing neoadjuvant treatment and within approximately 7 days following the [F-18]CP-18 PET/CT scan

• Patient has an adequate size breast tumor (=1.0 cm) that should be amenable to imaging

• Patient's tumor tissue is obtainable following surgery in order to perform immunohistochemistry staining using caspase 3 and/or other apoptosis biomarkers

• Patient must have a previous baseline (pre-neoadjuvant treatment) diagnostic imaging exam including but not limited to MRI, CT, mammography, or [F-18] FDG PET/CT scan that identifies breast tumor location

Exclusion Criteria:

For Normal Volunteers

• Subject is nursing

• Subject is pregnant

• Subject has been involved in an investigative, radioactive research procedure within the past 14 days

• Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality

For Cancer Patients

• Subject is nursing

• Subject is pregnant

• Subject has been involved in an investigative, radioactive research procedure within the past 14 days

• Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality

• Patient tumor tissue(s) is not obtainable after tumor resection for caspase 3 and/or other biomarker immunohistochemistry assays

• Patient has had or will have treatment intervention(s) between the [F-18]CP-18 PET/CT scan and tumor resection

• Patient has a history or current evidence of any condition, therapy, lab abnormality that, in the opinion of the study investigator or treating physicians might confound the results of the study or poses an additional risk to the patients by their participation in the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Radiation:
• [F18]CP-18 Injection
Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.

Locations

Country	Name	City	State
United States	University of California, Irvine	Irvine	California
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Siemens Molecular Imaging

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To collect biodistribution, dosimetry and metabolite profile of [F-18]CP-18 from normal subjects		Visit 2 and Visit 3	No
Secondary	To collect pre-dose and post-dose parameters of vital signs, ECG and CBC and clinical chemistry data along with monitoring any adverse events of the IP from normal and cancer subjects.		Visit 2 and Visit 3	Yes